Autumn 2014, Volume 11, Number 2

This CPI issue focuses primarily on two segments, product hopping and pay-for-delay. In the first piece, we look (1) “product hopping” from one version of a drug to another and (2) settlements by which brands pay generics to delay entry. Then, we look at regulatory approaches in the EU and U.S. on “evergreening,” FTC’s recent activities, and examine the growing interest outside the United States in getting into the “pay-for-delay” fray, how the Canadian competition authorities are dealing with the issue, how the Indian competition authority is looking at a pharma merger.